Neuroendocrine Tumors - Pipeline Review, H1 2016

Description:

Neuroendocrine Tumors - Pipeline Review, H1 2016

Summary

‘Neuroendocrine Tumors - Pipeline Review, H1 2016’, provides an overview of the Neuroendocrine Tumors pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Neuroendocrine Tumors
- The report reviews pipeline therapeutics for Neuroendocrine Tumors by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Neuroendocrine Tumors therapeutics and enlists all their major and minor projects
- The report assesses Neuroendocrine Tumors therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Neuroendocrine Tumors

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Neuroendocrine Tumors
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Neuroendocrine Tumors pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

Introduction
Neuroendocrine Tumors Overview
Therapeutics Development
Neuroendocrine Tumors - Therapeutics under Development by Companies
Neuroendocrine Tumors - Therapeutics under Investigation by Universities/Institutes
Neuroendocrine Tumors - Pipeline Products Glance
Neuroendocrine Tumors - Products under Development by Companies
Neuroendocrine Tumors - Products under Investigation by Universities/Institutes
Neuroendocrine Tumors - Companies Involved in Therapeutics Development
Neuroendocrine Tumors - Therapeutics Assessment
Drug Profiles
Neuroendocrine Tumors - Recent Pipeline Updates
Neuroendocrine Tumors - Dormant Projects
Neuroendocrine Tumors - Discontinued Products
Neuroendocrine Tumors - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Neuroendocrine Tumors, H1 2016
Number of Products under Development for Neuroendocrine Tumors - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Development by Companies, H1 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Products under Development by Companies, H1 2016 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2016

Neuroendocrine Tumors - Pipeline by Advanced Accelerator Applications S.A., H1 2016

Neuroendocrine Tumors - Pipeline by Aegis Therapeutics, LLC, H1 2016

Neuroendocrine Tumors - Pipeline by Amgen Inc., H1 2016

Neuroendocrine Tumors - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016

Neuroendocrine Tumors - Pipeline by Boehringer Ingelheim GmbH, H1 2016

Neuroendocrine Tumors - Pipeline by Chiasma, Inc., H1 2016

Neuroendocrine Tumors - Pipeline by Crinetics Pharmaceuticals, Inc., H1 2016

Neuroendocrine Tumors - Pipeline by Daiichi Sankyo Company, Limited, H1 2016

Neuroendocrine Tumors - Pipeline by Delcath Systems, Inc., H1 2016

Neuroendocrine Tumors - Pipeline by DexTech Medical AB, H1 2016

Neuroendocrine Tumors - Pipeline by Eisai Co., Ltd., H1 2016

Neuroendocrine Tumors - Pipeline by Exelixis, Inc., H1 2016

Neuroendocrine Tumors - Pipeline by Foresee Pharmaceuticals, LLC, H1 2016

Neuroendocrine Tumors - Pipeline by Hutchison MediPharma Limited, H1 2016

Neuroendocrine Tumors - Pipeline by Intezyne, Inc, H1 2016

Neuroendocrine Tumors - Pipeline by INVENT Pharmaceuticals, Inc., H1 2016

Neuroendocrine Tumors - Pipeline by Ipsen S.A., H1 2016

Neuroendocrine Tumors - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016

Neuroendocrine Tumors - Pipeline by Karyopharm Therapeutics, Inc., H1 2016

Neuroendocrine Tumors - Pipeline by Lexicon Pharmaceuticals, Inc., H1 2016

Neuroendocrine Tumors - Pipeline by Midatech Pharma Plc, H1 2016

Neuroendocrine Tumors - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016

Neuroendocrine Tumors - Pipeline by MolMed S.p.A., H1 2016

Neuroendocrine Tumors - Pipeline by Northwest Biotherapeutics, Inc., H1 2016

Neuroendocrine Tumors - Pipeline by Novartis AG, H1 2016

Neuroendocrine Tumors - Pipeline by OctreoPharm Sciences GmbH, H1 2016

Neuroendocrine Tumors - Pipeline by OXiGENE, Inc., H1 2016

Neuroendocrine Tumors - Pipeline by Peptron, Inc., H1 2016

Neuroendocrine Tumors - Pipeline by Pfizer Inc., H1 2016

Neuroendocrine Tumors - Pipeline by Pharma Mar, S.A., H1 2016
Neuroendocrine Tumors - Pipeline by Progenics Pharmaceuticals, Inc., H1 2016
Neuroendocrine Tumors - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2016
Neuroendocrine Tumors - Pipeline by Sompharmaceuticals S.A., H1 2016
Neuroendocrine Tumors - Pipeline by Strongbridge Biopharma plc, H1 2016
Neuroendocrine Tumors - Pipeline by Vascular Biogenics Ltd., H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Neuroendocrine Tumors Therapeutics - Recent Pipeline Updates, H1 2016
Neuroendocrine Tumors - Dormant Projects, H1 2016
Neuroendocrine Tumors - Discontinued Products, H1 2016
List of Figures
Number of Products under Development for Neuroendocrine Tumors, H1 2016
Number of Products under Development for Neuroendocrine Tumors - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Top 10 Routes of Administration, H1 2016
Number of Products by Stage and Top 10 Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Neuroendocrine Tumors - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3774184/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Description</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Account number</td>
<td>833 130 83</td>
</tr>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB9853308331083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World